Hem › Steatotisk leversjukdom › North Carolina
Kliniska studier för Steatotisk leversjukdom i North Carolina
13 studier för Steatotisk leversjukdom söker deltagare vid platser i North Carolina.
Städer i North Carolina
Officiell studietext (engelska)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- och 2 fler
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- och 3 fler
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 30 sep. 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Duke Liver Center, Durham
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 28 sep. 2026 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Duke University - Main Hospital and Clinics, Durham
- Monroe Biomedical Research, Monroe
- Carteret Medical Group, Morehead City
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chapel Hill
- Akero Clinical Study Site, Charlotte
- Akero Clinical Study Site, Charlotte
- och 5 fler
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 21 sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Morehead City
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 17 sep. 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 9 sep. 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chapel Hill
RekryterarFas 2
Ålder 18 till 70 · Alla kön · Uppdaterad 3 aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Morehead City
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 27 juli 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Wilson
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 8 juli 2026 · NCT06920043Androgens and NAFLD Longitudinal Cohort Study
- Duke University, Durham
RekryterarObservationsstudie
Ålder 18 till 42 · Kvinnor · Uppdaterad 13 apr. 2026 · NCT06124261Siemens Biomarker Multi-modality
- Duke University Medical Center, Durham
Rekryterar
Ålder 18 och äldre · Alla kön · Uppdaterad 3 apr. 2026 · NCT07495332Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.